Kidney cancer (renal cell carcinoma) often develops silently, with few symptoms until later stages. By the time it is clinically detected, disease progression may already be advanced. Molecular and immune system disruptions, however, begin much earlier.

The Kidney Immunocarcinogenic Assay evaluates immune and prometastatic biomarker patterns associated with kidney tumor development and progression. This test enhances traditional imaging and pathology by providing immune-molecular insight into early disease activity, recurrence risk, and treatment response.

Why This Test Matters

Key Benefits

Standard scans can miss early immune and molecular changes. The Kidney Immunocarcinogenic Assay detects these disruptions at the molecular level so patients and clinicians can act early.

Early Risk Identification

Detects molecular activity linked to kidney cancer initiation before advanced symptoms.

Precision Guidance

Provides actionable biomarker data to support targeted therapy and immunotherapy decisions.

Complementary Diagnostic Tool

Enhances imaging and histopathology with immune system context.

Treatment Monitoring

Tracks immune-molecular shifts during treatment and remission.

Physician-Ready Report Included

Results in
10-14 days

Reliable Results You Can Trust

Biomarkers Assessed

The Kidney Immunocarcinogenic Assay panel measures a targeted range of biomarkers to detect immune activity, tumor-promoting inflammation, and renal tumor progression:

  • Immune checkpoint activity (PD-L1, CTLA-4)

  • Angiogenesis factors (VEGF, FGF) related to kidney tumor vascularization

  • Inflammatory cytokines (IL-6, TNF-α, CRP)

  • Tumor microenvironment markers supporting metastasis

  • Metabolic stress and renal function-related biomarkers

Download a Sample Report

How It Works

Process

From registration to results, the process is simple, secure, and stress-free. One blood draw gives you answers that imaging can’t.

01

Order & Registration

Patient registers via the secure Persona Biomed portal.

02

Sample Collection

Standard blood draw performed at a certified site or through mobile phlebotomy.

03

Laboratory Analysis

Advanced assays quantify immune and prometastatic activity related to kidney tumors.

04

Results Delivery

Physician-ready report provided through the patient portal, with AI-powered plain-language summaries.

Who Should Consider This Test

who is this for

This test is intended for individuals who may be at risk, are experiencing related symptoms, or wish to take a proactive approach to their health, such as:

  • Patients with a family history of kidney cancer or known genetic predispositions.

  • Individuals with suspicious imaging or lab results requiring molecular confirmation.

  • Patients undergoing immunotherapy or targeted therapy for renal cancer.

  • Kidney cancer survivors who need recurrence monitoring.

Register Now for
Kidney Immunocarcinogenic Assay

Register now for the Kidney Immunocarcinogenic Assay to detect and monitor molecular signals of kidney cancer and guide personalized treatment strategies.

Register now